Silverberg JI, Simpson EL, Wollenberg A, et al. - Researchers sought to assess the long-term (68-week) efficacy of baricitinib, an oral selective Janus kinase inhibitor, in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders in BREEZE-AD1 and BREEZE-AD2. Patients who completed BREEZE-AD1/BREEZE-AD2 were enrolled in BREEZE-AD3, a multicenter, double-blind, long-term extension study. According to results, baricitinib, 4 mg, showed a slight decrease in EASI75 response among responders and partial responders, while baricitinib, 2 mg, showed a mostly stable response between weeks 16 and 68. Baricitinib, 4 and 2 mg, showed sustained long-term efficacy in patients with moderate to severe atopic dermatitis in this long-term double-blind extension study of 2 randomized clinical trials.